Parkinson's Neuroprotection 2025: Three Strategies Under Review
Stem cell therapy, System Xc- pathway modulation, and Ayurvedic add-on regimens are each being evaluated as neuroprotective strategies in Parkinson's disease.
Read article
Highlights
News
Cardiology|SSEPs to Monitor Cerebral Perfusion During TCAR TAVR ProceduresEndocrinology|Unraveling MASH: Implications for Clinical PracticeCardiology|TAVI and Aortic Dissection Risk: Is Valve Type a Factor?Critical Care|ECPR Rewarming: A Case for Prolonged Resuscitation?Endocrinology|Metformin, Liraglutide, and Gut Microbiome Shifts in Youth-Onset T2DGastroenterology|Endoluminal Markers Predict Crohn's Treatment FailureCardiology|Atrial Fibrillation Complexity: How Reliable is Registry Data?Geriatrics|Frailty Research Trends: What's Being Missed?Hepatology|Using Growth Charts in Alagille SyndromeEndocrinology|SGLT2 Inhibitors: Promise and Peril in Prader-Willi Syndrome?Cardiology|PCSK9 Inhibitors Move Upstream: Evolocumab Tested in Diabetes Without Known AtherosclerosisNephrology|Kidney Disease Diagnosis: The Promise of Urinary ExosomesCardiology|SSEPs to Monitor Cerebral Perfusion During TCAR TAVR ProceduresEndocrinology|Unraveling MASH: Implications for Clinical PracticeCardiology|TAVI and Aortic Dissection Risk: Is Valve Type a Factor?Critical Care|ECPR Rewarming: A Case for Prolonged Resuscitation?Endocrinology|Metformin, Liraglutide, and Gut Microbiome Shifts in Youth-Onset T2DGastroenterology|Endoluminal Markers Predict Crohn's Treatment FailureCardiology|Atrial Fibrillation Complexity: How Reliable is Registry Data?Geriatrics|Frailty Research Trends: What's Being Missed?Hepatology|Using Growth Charts in Alagille SyndromeEndocrinology|SGLT2 Inhibitors: Promise and Peril in Prader-Willi Syndrome?Cardiology|PCSK9 Inhibitors Move Upstream: Evolocumab Tested in Diabetes Without Known AtherosclerosisNephrology|Kidney Disease Diagnosis: The Promise of Urinary Exosomes